Phase I/II adaptive design for drug combination oncology trials

Statistics in Medicine

Volumn 33, Issue 12, 2014, Pages 1990-2003

  Wages, Nolan A ^a   Conaway, Mark R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adaptive randomization; Continual reassessment method; Dose finding; Drug combination; Phase II

Indexed keywords

ALGORITHM; ARTICLE; BAYES THEOREM; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; ONCOLOGY; OPTIMAL DOSE COMBINATION; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROBABILITY; RANDOMIZATION; SAMPLE SIZE; STUDY DESIGN; DOSE RESPONSE; MAXIMUM TOLERATED DOSE; METHODOLOGY; NEOPLASMS; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; MODELS, STATISTICAL; NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84899906158     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6097     Document Type: Article

References (26)

1. Yin G. Clinical Trial Design: Bayesian and Frequentist Adaptive Methods. John Wiley & Sons: Hoboken, New Jersey, 2012.
2. Gooley TA, Martin PJ, Fisher LD, Pettinger M. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Controlled Clinical Trials 1994; 15: 450-462.
3. Thall PF, Russell KT. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes on phase I/II clinical trials. Biometrics 1998; 54: 251-264.
4. O'Quigley J, Hughes MD, Fenton T. Dose-finding designs for HIV studies. Biometrics 2001; 57: 1018-1029.
5. Braun T. The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials 2002; 23: 240-256.
6. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004; 60: 684-693.
7. Yin G, Li Y, Ji Y. Bayesian dose finding in phase I/II clinical trials using toxicity and efficacy odds ratio. Biometrics 2006; 62: 777-787.
8. O'Quigley J, Conaway MR. Extended model-based designs for more complex dose-finding studies. Statistics in Medicine 2011; 30: 2062-2069.
9. Wages NA, O'Quigley J, Conaway MR. Phase I design for completely or partially ordered treatment schedules. Statistics in Medicine 2014; 33: 569-579.
10. Thall P, Milliken R, Mueller P, Lee SJ. Dose-finding with two agents in phase I oncology trials. Biometrics 2003; 59: 487-496.
11. Conaway M, Dunbar S, Peddada S. Designs for singe- or multiple-agent phase I trials. Biometrics 2004; 60: 661-669.
12. Wang K, Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics 2005; 61: 217-222.
13. Yin G, Yuan Y. A latent contingency table approach to dose-finding for combinations of two agents. Biometrics 2009; 65: 866-875.
14. Braun T, Wang S. A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents. Biometrics 2010; 66: 805-812.
15. Wages NA, Conaway MR, O'Quigley J. Continual reassessment method for partial ordering. Biometrics 2011; 67: 1555-1563.
16. Huang X, Biswas S, Oki Y, Issa JP, Berry D A. A parallel phase I/II clinical trial design for combination therapies. Biometrics 2007; 63: 429-436.
17. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45: 925-937.
18. Li Y, Bekele B, Ji Y, Cook J. Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Statistics in Medicine 2008; 27: 4895-4913.
19. Yuan Y, Yin G. Bayesian phase I/II adaptively randomized oncology trials with combined drugs. The Annals of Applied Statistics 2011; 5: 924-942.
20. Yin G, Yuan Y. Bayesian dose finding for drug combinations by copula regression. Journal of the Royal Statistical Society 2009; 58(2):211-224.
21. Wages NA, Conaway MR. Specifications of a continual reassessment method design for phase I trials of combined drugs. Pharmaceutical Statistics 2013; 12: 217-224.
22. Cheung YK. Dose-Finding by the Continual Reassessment Method. 1st ed. Chapman & Hall: Boca Raton, FL, 2011.
23. O'Quigley J, Zohar S. Retrospective robustness of the continual reassessment method. Journal of Biopharmaceutical Statistics 2010; 5: 1013-1025.
24. O'Quigley J, Shen L. Continual reassessment method: a likelihood approach. Biometrics 1996; 52: 673-684.
25. Lee SM, Cheung YK. Model calibration in the continual reassessment method. Clinical Trials 2009; 6(3):227-238.
26. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.